NEW YORK, August 28, 2026, 10:18 EDT
- Veeva was last at $281.08, holding onto a 14.8% rise from before its earnings announcement.
- Revenue for the quarter climbed 18% to $928.0 million, while GAAP operating income was up 40%.
- The rally following the results increased implied market value by approximately $6.0 billion.
Veeva Systems held onto most of its post-earnings gains on Friday, as higher subscription growth and expanding operating margins contributed to a valuation boost of about $6.0 billion.
Veeva Systems Inc. (NYSE: VEEV) stood at $281.08 at 10:18 EDT. The stock slipped 0.4% on Friday, but was still 14.8% higher than its closing price before earnings.
The life-sciences software firm posted fiscal second-quarter revenue of $928.0 million, marking an 18% increase from the previous year. Subscription revenue climbed 16% to reach $766.8 million quarterly results.
| Fiscal Q2 metric | 2027 | 2026 | Change |
|---|---|---|---|
| Total revenue | $928.0M | $789.1M | up 18% |
| Subscription revenue | $766.8M | $659.2M | rising 16% |
| GAAP operating income | $275.0M | $195.9M | an increase of 40% |
| GAAP net income | $273.4M | $200.3M | up 37% |
| Adjusted diluted EPS | $2.35 | $1.99 | increased by 18% |
The rerating was propelled by operating leverage. GAAP operating margin climbed to 29.6%, an increase of approximately 480 basis points. Revenue expanded at a pace that outstripped the rise in costs required to support it.
Vault CRM delivered another demonstration of its progress. Over 180 clients are now live on the platform, among them five leading biopharma firms from the global top 20. In total, twelve out of the top 20 have signed on to use the platform.
Management connected demand to agentic software. Veeva Falcon counts five early adopters and is still on track for first deployments later this year. Chief Executive Peter Gassner said AI was opening “the next big chapter” for Veeva and life sciences.
The company forecasts third-quarter revenue between $932 million and $935 million. It anticipates adjusted operating income ranging from $417 million to $420 million. Adjusted earnings per share are projected at $2.33 to $2.34.
The company now forecasts full-year revenue between $3.682 billion and $3.687 billion. Adjusted operating income is seen close to $1.64 billion. Veeva anticipates adjusted earnings to be around $9.21 per share.
Liquidity remains ample. As of July 31, cash and short-term investments stood at $7.24 billion, providing Veeva with sufficient resources to support product development and acquisitions without needing to dilute shareholders.
Analysts quickly adjusted their outlooks, with Thursday price targets stretching from $180 at Goldman Sachs up to $330 at Raymond James. The present average from 28 analysts stands at $292.22, roughly 4% higher than Friday’s closing price analyst consensus.
The slim average upside now presents a fresh obstacle. With shares trading at about 46 times trailing earnings, ongoing margin growth and resilient CRM conversions are required to justify the current valuation.
Risks: Major pharmaceutical implementations may move from one quarter to another. Subscription growth could be affected by competitive pricing, postponed migrations or a slower pace of AI adoption. Following results, the valuation offers less cushion for any shortfalls in execution.
Related articles: Earnings
